Adar1 Capital Management, Llc Purchases 6,400 Shares of NextCure (NASDAQ:NXTC) Stock

Posted by Geri Gentry on Jul 29th, 2026

NextCure, Inc. (NASDAQ:NXTC – Get Free Report) major shareholder Adar1 Capital Management, Llc purchased 6,400 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The stock was bought at an average cost of $4.95 per share, for a total transaction of $31,680.00. Following the completion of the acquisition, the insider directly owned 389,856 shares in the company, valued at $1,929,787.20. The trade was a 1.67% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

On Wednesday, July 29th, Adar1 Capital Management, Llc acquired 3,410 shares of NextCure stock. The shares were bought at an average price of $5.00 per share, with a total value of $17,050.00.
On Monday, July 27th, Adar1 Capital Management, Llc acquired 7,798 shares of NextCure stock. The stock was bought at an average cost of $5.00 per share, for a total transaction of $38,990.00.

NextCure Stock Performance

NXTC stock traded down $0.40 during mid-day trading on Wednesday, hitting $5.02. The company had a trading volume of 355,456 shares, compared to its average volume of 939,730. The firm has a market cap of $18.12 million, a PE ratio of -0.29 and a beta of 1.42. NextCure, Inc. has a 12 month low of $1.55 and a 12 month high of $15.74. The stock’s fifty day moving average price is $3.76 and its two-hundred day moving average price is $8.83.

NextCure (NASDAQ:NXTC – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23. Equities analysts anticipate that NextCure, Inc. will post -7.89 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Weiss Ratings downgraded NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Wall Street Zen cut NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of NextCure in a research note on Wednesday, July 15th. Finally, Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $19.00.

Read Our Latest Stock Report on NXTC

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Ikarian Capital LLC purchased a new position in NextCure in the 4th quarter valued at approximately $3,382,000. Squadron Capital Management LLC purchased a new stake in shares of NextCure during the fourth quarter worth $3,363,000. Exome Asset Management LLC bought a new position in shares of NextCure in the fourth quarter worth $2,341,000. AWM Investment Company Inc. bought a new position in shares of NextCure in the fourth quarter worth $1,665,000. Finally, Cable Car Capital LP boosted its holdings in shares of NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after acquiring an additional 88,040 shares during the period. 42.65% of the stock is owned by institutional investors.

About NextCure

(Get Free Report)

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.